MedDataX Logo

To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox

NCT00141479 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2015-01-16

No results posted yet for this study

Summary

The purpose of this study is to investigate a safe treatment interruption interval(s) for re-initiation of bifeprunox at a therapeutic dose. The study duration is approximately 7 to 10 weeks.

Conditions

  • Schizophrenia
  • Schizoaffective Disorder

Interventions

DRUG

Bifeprunox

Sponsors & Collaborators

  • H. Lundbeck A/S

    collaborator INDUSTRY

  • Wyeth is now a wholly owned subsidiary of Pfizer

    collaborator INDUSTRY

  • Solvay Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Global Clinical Director Solvay · Solvay Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2006-11-30
Completion
2006-11-30

Countries

  • United States

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00141479 on ClinicalTrials.gov